Astrana Health Inc (ASTH) Stock Analysis
Verdict: WATCH (do not buy)
Aggressive revenue scaling via M&A is masking severe margin volatility and recent earnings inconsistency, demanding a cautious entry.
Investment score: 58/100
Analysis as of
Is Astrana Health Inc stock worth reviewing? The TradeMates thesis
The TradeMates model views ASTH as a high-growth scale play in value-based care that is currently digestive a massive price run. Fundamental concerns regarding margin compression and debt levels outweigh the consensus analyst optimism in the immediate term.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Astrana Health Inc opportunities and risks
What speaks for ASTH
- Accelerated Revenue Scaling
What speaks against ASTH
- Severe Earnings Unpredictability
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ASTH | 66.1x | 0.6x | 16.0x | 9.3% | 0.9% | 7.7% |
| PRVA | 143.0x | 1.4x | 49.2x | 9.6% | 1.0% | 4.3% |
| CRVL | 27.2x | 3.1x | 15.9x | 24.3% | 11.5% | 3.7% |
| GRDN | 45.4x | 1.7x | 23.6x | 20.9% | 3.6% | 2.9% |
| PINC | 60.3x | 0.0x | 1.5x | 73.0% | 9.4% | 702.2% |
| MD | 12.3x | 1.1x | 9.0x | 25.8% | 9.0% | 11.4% |
| Peer median | 45.4x | 1.4x | 15.9x | 24.3% | 9.0% | 4.3% |
Frequently asked questions about Astrana Health Inc (ASTH)
Is ASTH stock a good investment?
The TradeMates model rates Astrana Health Inc as WATCH (do not buy) with an investment score of 58/100. The TradeMates model views ASTH as a high-growth scale play in value-based care that is currently digestive a massive price run. Fundamental concerns regarding margin compression and debt levels outweigh the consensus analyst optimism in the immediate term. This is algorithmic model output, not personal investment advice.
Is ASTH stock a buy?
The TradeMates model verdict for ASTH is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.